CA2992282A1 - Transpapillary methods and compositions for treating breast disorders - Google Patents
Transpapillary methods and compositions for treating breast disorders Download PDFInfo
- Publication number
- CA2992282A1 CA2992282A1 CA2992282A CA2992282A CA2992282A1 CA 2992282 A1 CA2992282 A1 CA 2992282A1 CA 2992282 A CA2992282 A CA 2992282A CA 2992282 A CA2992282 A CA 2992282A CA 2992282 A1 CA2992282 A1 CA 2992282A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- breast
- carcinoma
- nipple
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Materials For Medical Uses (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192505P | 2015-07-14 | 2015-07-14 | |
| US62/192,505 | 2015-07-14 | ||
| PCT/US2016/042202 WO2017011623A1 (en) | 2015-07-14 | 2016-07-14 | Transpapillary methods and compositions for treating breast disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2992282A1 true CA2992282A1 (en) | 2017-01-19 |
Family
ID=57757662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2992282A Abandoned CA2992282A1 (en) | 2015-07-14 | 2016-07-14 | Transpapillary methods and compositions for treating breast disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180200206A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3322406A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018520182A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108024959A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016294526A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2992282A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017011623A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3283061A4 (en) * | 2015-04-14 | 2019-04-17 | Atossa Genetics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES |
| EP3679061A4 (en) * | 2017-09-06 | 2021-06-09 | University of Cincinnati | METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| CN110221068B (zh) * | 2018-03-02 | 2020-09-18 | 中国医学科学院基础医学研究所 | 检测Kyn含量的试剂的应用 |
| WO2021003433A1 (en) | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US6398765B1 (en) * | 1999-03-01 | 2002-06-04 | Pro Duct Health, Inc. | Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts |
| US20020117169A1 (en) * | 2001-02-27 | 2002-08-29 | Kurz Daniel R. | Cover and applicator for a portion of a mammalian body |
| JP2004530659A (ja) * | 2001-02-28 | 2004-10-07 | ジャイルズ,ブライアン,シー. | 抗腫瘍および抗転移作用のための方法および処方 |
| DE60322191D1 (de) * | 2002-03-19 | 2008-08-28 | Cytyc Corp | Intraduktale behandlung von brustläsionen umfassend therapeutische und diagnostische mittel |
| US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| KR100419298B1 (ko) * | 2003-07-28 | 2004-02-18 | 조규학 | 부착형 브래지어 및 그 제조방법 |
| US7229420B2 (en) * | 2003-12-23 | 2007-06-12 | Cytyc Corporation | Medical instrument for accessing a breast duct for performing a medical procedure |
| US20050142315A1 (en) * | 2003-12-24 | 2005-06-30 | Desimone Joseph M. | Liquid perfluoropolymers and medical applications incorporating same |
| IL177006A0 (en) * | 2005-08-02 | 2006-12-10 | Veridex Llc | Predicting bone relapse of breast cancer |
| WO2007067773A2 (en) * | 2005-12-09 | 2007-06-14 | Mayo Foundation For Medical Education And Research | Assessing outcomes for breast cancer patients by determining cyp2d6 genotype |
| ES2539042T3 (es) * | 2006-06-02 | 2015-06-25 | Glaxosmithkline Biologicals S.A. | Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia |
| PT2101731T (pt) * | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| WO2009105640A1 (en) * | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| WO2009129352A2 (en) * | 2008-04-15 | 2009-10-22 | Windy Hill Medical | Device and method for accessing and treating ducts of mammary glands |
| WO2010009335A1 (en) * | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| ES2624557T3 (es) * | 2008-12-11 | 2017-07-14 | Besins Healthcare Luxembourg Sarl | Composiciones farmacéuticas transdérmicas que comprenden un SERM |
| WO2011072244A1 (en) * | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
| EP2425833A1 (de) * | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
| US20130045179A1 (en) * | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
| US9517183B2 (en) * | 2012-01-30 | 2016-12-13 | Patrick B. Ward | Nipple abrasion protector |
| WO2013134230A1 (en) * | 2012-03-05 | 2013-09-12 | Xavier University | Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer |
| US9220680B2 (en) * | 2012-07-13 | 2015-12-29 | South Dakota State University | Compositions and methods for localized drug delivery through mammary papillae |
| EP3092027A4 (en) * | 2014-01-10 | 2017-09-06 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| EP3283061A4 (en) * | 2015-04-14 | 2019-04-17 | Atossa Genetics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES |
-
2016
- 2016-07-14 CA CA2992282A patent/CA2992282A1/en not_active Abandoned
- 2016-07-14 US US15/744,004 patent/US20180200206A1/en not_active Abandoned
- 2016-07-14 JP JP2018501348A patent/JP2018520182A/ja active Pending
- 2016-07-14 EP EP16825155.1A patent/EP3322406A4/en not_active Withdrawn
- 2016-07-14 AU AU2016294526A patent/AU2016294526A1/en not_active Abandoned
- 2016-07-14 WO PCT/US2016/042202 patent/WO2017011623A1/en not_active Ceased
- 2016-07-14 CN CN201680052914.XA patent/CN108024959A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016294526A1 (en) | 2018-02-08 |
| JP2018520182A (ja) | 2018-07-26 |
| EP3322406A1 (en) | 2018-05-23 |
| WO2017011623A1 (en) | 2017-01-19 |
| CN108024959A (zh) | 2018-05-11 |
| US20180200206A1 (en) | 2018-07-19 |
| EP3322406A4 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016294526A1 (en) | Transpapillary methods and compositions for treating breast disorders | |
| Rizzoli et al. | Cancer-associated bone disease | |
| Carlson et al. | Invasive breast cancer | |
| Berruti et al. | Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| Brown et al. | Denosumab in patients with cancer—a surgical strike against the osteoclast | |
| Paridaens et al. | Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer | |
| Kataja et al. | Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | |
| Moncayo et al. | Status of sentinel lymph node for breast cancer | |
| Park-Simon et al. | AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2025 | |
| US20160375234A1 (en) | Transpapillary methods and compositions for diagnosing and treating breast conditions | |
| HUP0300339A2 (hu) | Fulvesztrant felhasználása rezisztens emlőrák kezelésében | |
| Theivendren et al. | The future perspectives of drug repurposing and treatment for the drug resistant breast cancer | |
| Sowa-Staszczak et al. | Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors? | |
| Kamaraju et al. | A phase II trial of onapristone and fulvestrant for patients with ER+ and HER2-metastatic breast cancer | |
| Kaufmann et al. | Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer | |
| Somashekhar et al. | Association of Breast Surgeons of India (ABSI) practical consensus statement, recommendations, and guidelines for the treatment of breast cancer in India 2021—Indian solutions for Indian problems | |
| Müssig et al. | Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension | |
| HK1255302A1 (en) | Transpapillary methods and compositions for treating breast disorders | |
| Manzone et al. | Postoperative management of thyroid carcinoma | |
| Breast Cancer Expert Committee of the National Quality Control Center for Cancer et al. | Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition) | |
| Dietl et al. | FDG-PET in radiotherapy treatment planning of advanced head and neck cancer—a prospective clinical analysis | |
| Sharma et al. | Recent development in treatment strategies for breast cancer: With special reference to immunotherapy | |
| Hu et al. | Effect of cisplatin arterial infusion (CAI) on primary nonmetastatic pelvic osteosarcoma: a preliminary study | |
| Simeone | Pain and analgesic use associated with sres in patients with advanced breast cancer and bone metastases treated with bone-modifying agents: a retrospective observational study | |
| Chin | Advancing Surgical Strategies for Breast Cancer in the Era of Neoadjuvant Chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20221004 |